CSDD


Also found in: Medical.
AcronymDefinition
CSDDCenter for the Study of Drug Development (Tufts University)
CSDDControl Systems Development Division (JSC)
CSDDConceptual System Design Description
CSDDCelu Satiksmes Drošibas Direkcija (Latvian: Central Department of Traffic Safety)
CSDDComputer Subprogram Design Document
CSDDComputer Software Design Description (usually called SDD)
CSDDConsolidated Software Design Document
References in periodicals archive ?
Tufts CSDD developed a web survey in collaboration with industry thought leaders to assess CRO precision medicine capacity and readiness.
We are excited to be working alongside the Tufts CSDD, regulatory authorities and other industry colleagues to help deliver the value that adaptive design will bring to our industry.
At 13 weeks, the severity of depression decreased in all three groups, but the greatest reduction in CSDD scores occurred with placebo (-5.
The means reveal that there was a significant decrease in pain on the FLACC and PAINAD scales for residents in both conditions and a decrease in the Behavioral Disturbances subscale of the CSDD (Table 2).
We identified 1 study evaluating the CSDD that met our criteria.
Drug development remains a costly undertaking despite ongoing efforts across the full spectrum of pharmaceutical and biotech companies to rein in growing R&D costs," said Joseph DiMasi, director of economic analysis at Tufts CSDD and principal investigator for the study.
Medidata Designer was key to the Tufts CSDD team's ability to collect information for the study, as it is the only tool to offer clinical trial sponsors visibility into cost and complexity metrics, as well as the structuring capabilities crucial for identifying unnecessary procedures during the study design stage.
The Tufts CSDD Outlook 2014 report on pharmaceutical and biopharmaceutical trends also predicted that growing concern over expensive, late stage clinical development failures will lead firms to reassess their use of meta-analyses and subgroup analysis and make more realistic assessments about the likelihood that candidate drugs will succeed.
Tufts CSDD research indicates that the number of open innovation partnerships -- including public-private partnerships and integrated pharmaceutical development alliances -- has been rising sharply during the past several years, most notably those involving top 30 pharmaceutical and biotechnology companies.
A new analysis by Tufts CSDD shows investments in new immuno-oncology drugs, along with dramatic improvements in complete response rates in trials for new therapies, are helping to increase the number of alliances between pharma and biopharma companies and university and cancer centers.
The transformation of Big Pharma has been driven as much by new technologies that have enabled development of new products that improve disease outcomes and command high prices as by the expiring patents on many top-selling small molecule drugs, according to Tufts CSDD director Kenneth Kaitin.